Last reviewed · How we verify
adapalene 0.3% topical gel
At a glance
| Generic name | adapalene 0.3% topical gel |
|---|---|
| Sponsor | Actavis Mid-Atlantic LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Experience With Topical Acne Treatment (EARLY_PHASE1)
- A Treatment for Severe Inflammatory Acne Subjects (PHASE4)
- Effects of Oral Zinc Gluconate Among Acne Vulgaris Patients (PHASE4)
- Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars (PHASE2)
- Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris (PHASE3)
- Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris (PHASE3)
- The Use of Oracea and Epiduo Forte in Severe Acne Patients (PHASE4)
- Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- adapalene 0.3% topical gel CI brief — competitive landscape report
- adapalene 0.3% topical gel updates RSS · CI watch RSS
- Actavis Mid-Atlantic LLC portfolio CI